Hyperphosphatemia, or elevated blood phosphorus, is a prevalent issue in chronic kidney disease patients on dialysis, affecting over 80% of this population and linked to higher morbidity and mortality. Clinical guidelines recommend reducing phosphate levels to the 2.5 to 4.5?mg/dL range, and yet an estimated 75% of U.S. dialysis patients remain uncontrolled.
The company we are profiling today is Unicycive Therapeutics Inc. (UNCY), which is developing a treatment for hyperphosphatemia in patients with chronic kidney disease who are on dialysis.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.